Cullen Capital Management LLC Invests $65.25 Million in Bristol Myers Squibb Company $BMY

Cullen Capital Management LLC bought a new position in Bristol Myers Squibb Company (NYSE:BMY) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 1,132,367 shares of the biopharmaceutical company’s stock, valued at approximately $65,247,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Swiss RE Ltd. purchased a new stake in Bristol Myers Squibb in the fourth quarter worth about $25,000. Darwin Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb during the 2nd quarter valued at about $25,000. Physician Wealth Advisors Inc. grew its stake in shares of Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 202 shares during the period. Davis Asset Management L.P. purchased a new stake in Bristol Myers Squibb in the 2nd quarter worth approximately $27,000. Finally, Bayban purchased a new stake in Bristol Myers Squibb in the 4th quarter worth approximately $31,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol Myers Squibb Trading Up 0.4%

Shares of BMY opened at $67.30 on Tuesday. The firm has a market cap of $137.47 billion, a P/E ratio of 14.82, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $68.64. The company has a 50 day simple moving average of $60.77 and a two-hundred day simple moving average of $59.47.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. During the same quarter in the previous year, the firm earned $1.46 earnings per share. The company’s quarterly revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities analysts expect that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were paid a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 3.7%. Bristol Myers Squibb’s dividend payout ratio is currently 55.51%.

Analysts Set New Price Targets

Several brokerages have weighed in on BMY. Citigroup reaffirmed a “neutral” rating and set a $70.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, August 3rd. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. Piper Sandler started coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They set an “overweight” rating on the stock. Sanford C. Bernstein raised shares of Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a report on Wednesday, August 5th. Finally, Roth Capital assumed coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “buy” rating and a $75.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Moderate Buy” and a consensus target price of $66.06.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.